MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2016 International Congress

    Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

    S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…
  • 2016 International Congress

    Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON

    H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

    Objective: Evaluate whether baseline disease severity is predictive of the effective APL-130277 dose to turn a patient with Parkinson's disease (PD) from OFF to fully…
  • 2016 International Congress

    Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study

    A. Agro, B. Dzyngel, T. Bilbault, E.J. Pappert (Toronto, ON, Canada)

    Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…
  • 2016 International Congress

    APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa

    H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, R. Hauser, S. Isaacson (Phoenix, AZ, USA)

    Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…
  • 2016 International Congress

    Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease

    E.J. Pappert, B. Dzyngel, T. Bilbault, A. Agro (Toronto, ON, Canada)

    Objective: Determine the pharmacokinetic/pharmacodynamic effects of APL-130277 on OFF episodes in patients with Parkinson's disease (PD). Background: APL-130277 is a sublingual film being studied in…
  • 2016 International Congress

    Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

    H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

    Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…
  • 2016 International Congress

    PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program

    J.P. Hubble, B. Fisher, K. Lyons, C. McLean, G. Petzinger, R. Pahwa (Louisville, KY, USA)

    Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…
  • 2016 International Congress

    Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece

    G.A. Tagaris, A. Skafida, D. Athanasopoulos, E. Trachani, S. Tsiara (Athens, Greece)

    Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…
  • 2016 International Congress

    Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital

    K. Nalamada, J. Cosgrove, P. Duggan-Carter, S. Jamieson, J. Alty (Leeds, United Kingdom)

    Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley